March 2020 Quarterly Activities and Cash Flow Report
Filed with ASX · · 8 pages · English
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Successful Efficacy Result on Path to First in Human Studies
- Investor Presentation - February 2020
- CEO Appointment and Establishment of US Office
- Expansion Of Drug Development Pipeline
- Appendix 4C - quarterly
Later from PYC Therapeutics
- S&P DJI Announces June 2020 Quarterly Rebalance
- Successful Dose Response & Toxicity Studies in Lead Program
- June 2020 Quarterly Activity Report and Cashflow
- Shareholder Update - Forward View 2020 Milestones
- Executive re-structure across global operations
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics